Is it beneficial to the state to provide insulin-treated diabetic patients with public funds for self-monitoring blood glucose?

Background. In Russia, the prevalence of diabetes continues to increase with the growing diabetes epidemic. In recent years, the paradigm of diabetes treatment has been changing, with patients increasingly becoming equal participants in the treatment process, through the introduction of sel...

Full description

Saved in:
Bibliographic Details
Main Authors: Larisa Dmitrievna Popovich, Marina Vladimirovna Shestakova, Elena Georgievna Potapchik, Alexander Yur'evich Mayorov, Olga Konstantinovna Vikulova
Format: Article
Language:English
Published: Endocrinology Research Centre 2017-06-01
Series:Сахарный диабет
Subjects:
Online Access:https://www.dia-endojournals.ru/jour/article/view/8305
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849729814967091200
author Larisa Dmitrievna Popovich
Marina Vladimirovna Shestakova
Elena Georgievna Potapchik
Alexander Yur'evich Mayorov
Olga Konstantinovna Vikulova
author_facet Larisa Dmitrievna Popovich
Marina Vladimirovna Shestakova
Elena Georgievna Potapchik
Alexander Yur'evich Mayorov
Olga Konstantinovna Vikulova
author_sort Larisa Dmitrievna Popovich
collection DOAJ
description Background. In Russia, the prevalence of diabetes continues to increase with the growing diabetes epidemic. In recent years, the paradigm of diabetes treatment has been changing, with patients increasingly becoming equal participants in the treatment process, through the introduction of self-monitoring blood glucose (SMBG). Several clinical studies have demonstrated a positive relationship between SMBG and the decline of the epidemiological and economic burden of diabetes. At present, the procurement of public funds for SMBG is below the specified level in Russia. Aims. To investigate the potential macroeconomic benefits of public health resource allocation and the use of planned state investments to fund SMBG in insulin-treated diabetic patients. Materials and methods. This study was conducted with data from insulin-treated diabetic patients. The epidemiological burden of this cohort was determined by the following indicators: the number of patients and the incidence of complications resulting from diabetes, disability, mortality, age and sex. The economic benefits were evaluated by the implementation of two measures: (1) procurement of public funds for the purchase of means for SMBG in patients with insulin-treated diabetes and (2) the use of highly accurate blood glucose metres. To evaluate economic burden, the epidemiological burden was translated into monetary terms using cost-of-illness. Economic benefits were defined as reductions in economic burden. Results. The economic benefits of public-funded blood glucose test strips for insulin-treated diabetic patients exceeded the required additional investments for their purchase by 1.5 fold. A significant reduction in the inaccuracy of blood glucose metres from 20% to 10% may reduce the economic burden by 9.36 billion RUB. The combined state benefits from the implementation of both measures would significantly decrease the economic burden of diabetes to 29.2 billion RUB. Conclusions. Increased procurement of public funds for SMBG in insulin-treated diabetic patients would bring economic benefits that far exceed the required investments.
format Article
id doaj-art-823ef1d5fdd8408c8bec2fec5f1c48ef
institution DOAJ
issn 2072-0351
2072-0378
language English
publishDate 2017-06-01
publisher Endocrinology Research Centre
record_format Article
series Сахарный диабет
spelling doaj-art-823ef1d5fdd8408c8bec2fec5f1c48ef2025-08-20T03:09:04ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782017-06-0120210811810.14341/70777832Is it beneficial to the state to provide insulin-treated diabetic patients with public funds for self-monitoring blood glucose?Larisa Dmitrievna Popovich0Marina Vladimirovna Shestakova1Elena Georgievna Potapchik2Alexander Yur'evich Mayorov3Olga Konstantinovna Vikulova4<p>National Research University Higher School of Economics</p><p>Endocrinology Research Centre</p><p>National Research University Higher School of Economics</p><p>Endocrinology Research Centre</p><p>Endocrinology Research Centre</p>Background.&nbsp;In Russia, the prevalence of diabetes continues to increase with the growing diabetes epidemic. In recent years, the paradigm of diabetes treatment has been changing, with patients increasingly becoming equal participants in the treatment process, through the introduction of self-monitoring blood glucose (SMBG). Several clinical studies have demonstrated a positive relationship between SMBG and the decline of the epidemiological and economic burden of diabetes. At present, the procurement of public funds for SMBG is below the specified level in Russia. Aims.&nbsp;To investigate the potential macroeconomic benefits of public health resource allocation and the use of planned state investments to fund SMBG in insulin-treated diabetic patients. Materials and methods.&nbsp;This study was conducted with data from insulin-treated diabetic patients. The epidemiological burden of this cohort was determined by the following indicators: the number of patients and the incidence of complications resulting from diabetes, disability, mortality, age and sex. The economic benefits were evaluated by the implementation of two measures: (1) procurement of public funds for the purchase of means for SMBG in patients with insulin-treated diabetes and (2) the use of highly accurate blood glucose metres. To evaluate economic burden, the epidemiological burden was translated into monetary terms using cost-of-illness. Economic benefits were defined as reductions in economic burden. Results.&nbsp;The economic benefits of public-funded blood glucose test strips for insulin-treated diabetic patients exceeded the required additional investments for their purchase by 1.5 fold. A significant reduction in the inaccuracy of blood glucose metres from 20% to 10% may reduce the economic burden by 9.36 billion RUB. The combined state benefits from the implementation of both measures would significantly decrease the economic burden of diabetes to 29.2 billion RUB. Conclusions. Increased procurement of public funds for SMBG in insulin-treated diabetic patients would bring economic benefits that far exceed the required investments.https://www.dia-endojournals.ru/jour/article/view/8305the burden of diabetesself-controleconomic benefits
spellingShingle Larisa Dmitrievna Popovich
Marina Vladimirovna Shestakova
Elena Georgievna Potapchik
Alexander Yur'evich Mayorov
Olga Konstantinovna Vikulova
Is it beneficial to the state to provide insulin-treated diabetic patients with public funds for self-monitoring blood glucose?
Сахарный диабет
the burden of diabetes
self-control
economic benefits
title Is it beneficial to the state to provide insulin-treated diabetic patients with public funds for self-monitoring blood glucose?
title_full Is it beneficial to the state to provide insulin-treated diabetic patients with public funds for self-monitoring blood glucose?
title_fullStr Is it beneficial to the state to provide insulin-treated diabetic patients with public funds for self-monitoring blood glucose?
title_full_unstemmed Is it beneficial to the state to provide insulin-treated diabetic patients with public funds for self-monitoring blood glucose?
title_short Is it beneficial to the state to provide insulin-treated diabetic patients with public funds for self-monitoring blood glucose?
title_sort is it beneficial to the state to provide insulin treated diabetic patients with public funds for self monitoring blood glucose
topic the burden of diabetes
self-control
economic benefits
url https://www.dia-endojournals.ru/jour/article/view/8305
work_keys_str_mv AT larisadmitrievnapopovich isitbeneficialtothestatetoprovideinsulintreateddiabeticpatientswithpublicfundsforselfmonitoringbloodglucose
AT marinavladimirovnashestakova isitbeneficialtothestatetoprovideinsulintreateddiabeticpatientswithpublicfundsforselfmonitoringbloodglucose
AT elenageorgievnapotapchik isitbeneficialtothestatetoprovideinsulintreateddiabeticpatientswithpublicfundsforselfmonitoringbloodglucose
AT alexanderyurevichmayorov isitbeneficialtothestatetoprovideinsulintreateddiabeticpatientswithpublicfundsforselfmonitoringbloodglucose
AT olgakonstantinovnavikulova isitbeneficialtothestatetoprovideinsulintreateddiabeticpatientswithpublicfundsforselfmonitoringbloodglucose